Predict your next investment

Corporation
HEALTHCARE | Drug Development
themedicinescompany.com

See what CB Insights has to offer

Competitors

13

Business Relationships

10

Service Providers

5

The Medicines Company Competitors & Alternatives

13 Competitors

The Medicines Company has 13 competitors. The Medicines Company's competitors are Alnylam Pharmaceuticals, Ra Pharmaceuticals, SynDevRx, Milestone Pharmaceuticals, NanoString Technologies and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

4/13/2020

Corporate Minority - P2P

$67.32M

Massachusetts

4/2/2020

Acq - P2P

$77.56M

Massachusetts

1/17/2020

Debt - III

$34.61M

Massachusetts

5/9/2019

IPO

$165M

Canada

6/26/2013

IPO

$104.64M

Washington

6/21/2013

Entelos

Private Equity

$50.6M

California

2/5/2010

CytoSolv

Seed

$0.5M

Rhode Island

11/21/2008

Cogentus Pharmaceuticals

Unattributed VC

$168M

California

1/5/2004

Auxeris Therapeutics

Series A

$4.1M

Missouri

4/18/2003

Benten BioServices

PIPE - II

$37.05M

Pennsylvania

Latest Funding

4/13/2020

4/2/2020

1/17/2020

5/9/2019

6/26/2013

6/21/2013

2/5/2010

11/21/2008

1/5/2004

4/18/2003

Companies

Entelos

CytoSolv

Cogentus Pharmaceuticals

Auxeris Therapeutics

Benten BioServices

Investment Stage

Corporate Minority - P2P

Acq - P2P

Debt - III

IPO

IPO

Private Equity

Seed

Unattributed VC

Series A

PIPE - II

Total Funding

$67.32M

$77.56M

$34.61M

$165M

$104.64M

$50.6M

$0.5M

$168M

$4.1M

$37.05M

Mosaic

Location

Massachusetts

Massachusetts

Massachusetts

Canada

Washington

California

Rhode Island

California

Missouri

Pennsylvania

The Medicines Company Service Providers

5 Service Providers

The Medicines Company has 5 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Investment Bank

Bookrunner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Bookrunner

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

The Medicines Company Partners & Customers

10 Partners and customers

The Medicines Company has 10 strategic partners and customers. The Medicines Company recently partnered with Alnylam Pharmaceuticals on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/6/2017

Partner

Alnylam Pharmaceuticals

United States

The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

The Medicine 's Company and Alnylam Pharmaceuticals , Inc. are collaborating in the advancement of inclisiran pursuant to the terms of their 2013 agreement .

2

3/17/2017

Partner

Alnylam Pharmaceuticals

United States

The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

The Medicine 's Company and Alnylam Pharmaceuticals , Inc. are collaborating in the advancement of inclisiran pursuant to the terms of their 2013 agreement .

5

2/8/2017

Partner

Alnylam Pharmaceuticals

United States

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals , Inc. 's partner , The Medicine 's Company , announced positive results from the Day 90 interim analysis at the 2016 American Heart Association meeting and top-line Day 180 results for all 501 patients in the ongoing ORION-1 Phase 2 study of inclisiran , an investigational RNAi therapeutic for the treatment of hypercholesterolemia .

7

9/1/2016

Partner

Biomedical Advanced Research and Development Authority

United States

Subscribe to see more

Subscribe to see more

10

10/6/2015

Licensee

SymBio Pharmaceuticals

Japan

Subscribe to see more

Subscribe to see more

10

Date

11/6/2017

3/17/2017

2/8/2017

9/1/2016

10/6/2015

Type

Partner

Partner

Partner

Partner

Licensee

Business Partner

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Biomedical Advanced Research and Development Authority

SymBio Pharmaceuticals

Country

United States

United States

United States

United States

Japan

News Snippet

The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

The Medicine 's Company and Alnylam Pharmaceuticals , Inc. are collaborating in the advancement of inclisiran pursuant to the terms of their 2013 agreement .

The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

The Medicine 's Company and Alnylam Pharmaceuticals , Inc. are collaborating in the advancement of inclisiran pursuant to the terms of their 2013 agreement .

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals , Inc. 's partner , The Medicine 's Company , announced positive results from the Day 90 interim analysis at the 2016 American Heart Association meeting and top-line Day 180 results for all 501 patients in the ongoing ORION-1 Phase 2 study of inclisiran , an investigational RNAi therapeutic for the treatment of hypercholesterolemia .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

5

7

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.